Ultrasound Guided Lateral Femoral Cutaneous Block (LFCNB) And Femoral Nerve Block (FNB) For Postoperative Pain Control After Hip Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02056145

Enrollment

210

Registered

2014-02-05

Start date

2011-10-31

Completion date

2014-08-31

Last updated

2014-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

-Postoperative Pain

Brief summary

Evaluation of the combination of lateral femoral cutaneous nerve single shot and femoral nerve single shot block as effective and safe alternative postoperative analgesic technique after hip replacement surgery.

Detailed description

Clinical evaluation via a prospective, double-blinded, randomized clinical trial, whether ultrasound-guided single femoral block and lateral femoral cutaneous nerve blocks with 20 en 10 cc bupivacaine 0.25% respectively vs. the only ultrasound-guided single femoral block with 20 cc bupivacaine 0.25%, given just prior to elective hip surgery procedure, is effective in reducing acute postoperative pain (VAS scores) and postoperative opiate consumption.

Interventions

PROCEDURELFCNB

LFCNB - Normal Saline solution 10 cc

PROCEDUREFNB

FNB - Normal saline solution 10 cc

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Primary hip arthroplasty with posterolateral approach.

Exclusion criteria

* Known allergy to levobupivacaine and / or piritramide * Known neurological disorders or peripheral neuropathies * Existing drug or alcohol abuse * Chronic use of pain medication (\> started 3 months ago) not related to the hip suffering * Coagulopathy (international normalized ratio) \> 1.4 * Thrombocytopenia \<70,000 platelets, * Dementia * Pregnancy * Local infection hip * Hepatic and / or renal impairment * BMI\> 45.

Design outcomes

Primary

Measure	Time frame	Description
Use of opioids	48 hours	The primary outcome measure will be a consumption of opioids through the Intravenous Patient Controlled Analgesia pump. Those amounts will be measured en documented at the fixed intervals during the first 48 hours post-procedure.

Secondary

Measure	Time frame	Description
Visual analog scale (VAS) scores (0-10)	48 hours	The secondary outcome measure will be pain scores (VAS 0-10). Those scores will be measured en documented at the fixed intervals during the first 48 hours post-procedure.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026